AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10964861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 635
Study 10964861 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 635
Study 8639722 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral diet
Number of subjects: 60
Study 8639722 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched enteral diet (with arginine, RNA, and omega-3 fatty acids)
Number of subjects: 60
Study 8639722 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 60
Study 1851578 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus lonidamine
Number of subjects: 6
Study 1851578 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 6
Study 6421083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cream containing 0.5 mg estriol (OvestinR)
Number of subjects: 30
Study 6421083 — intervention group
Group type: COMPARATOR
Intervention: Vaginal suppositories containing 0.5 mg estriol (OvestinR)
Number of subjects: 30
Study 30747707 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary long-term prophylaxis (PRO) with vWF/FVIII concentrates
Number of subjects: 19
Study 30747707 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment (ODT) with vWF/FVIII concentrates
Number of subjects: 19
Study 29437056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g intra-articularly after closure of the wound
Number of subjects: 182
Study 29437056 — intervention group
Group type: COMPARATOR
Intervention: Two doses of 10 mg/kg IV
Number of subjects: 182
Study 29437056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (intra-articular and IV)
Number of subjects: 182
Study 26323998 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Ultrasonography course
Number of subjects: 31
Study 26323998 — intervention group
Group type: COMPARATOR
Intervention: Control circumstances
Number of subjects: 31
Study 23988395 — intervention group
Group type: COMPARATOR
Intervention: Short‐Term Executive Plus (STEP) program: 12 weeks (9h/wk) of group training in problem solving and emotional regulation and individual sessions of attention and compensatory strategies training.
Number of subjects: 98
Study 22915083 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive relationship prime
Number of subjects: 0
Study 22915083 — intervention group
Group type: COMPARATOR
Intervention: Nonsupportive relationship prime
Number of subjects: 0
Study 20124114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2-g/d omega-3 PUFA
Number of subjects: 81
Study 20124114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 18795194 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference‐Focused Psychotherapy (TFP)
Number of subjects: 90
Study 18795194 — intervention group
Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 90
Study 18795194 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 90
Study 15893433 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention
Number of subjects: 83
Study 15893433 — intervention group
Group type: COMPARATOR
Intervention: Internet-based intervention + self-help book
Number of subjects: 83
Study 11920412 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg, intravenous loading dose at weeks 0, 2, and 6)
Number of subjects: 40
Study 11920412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11920412 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 40
Study 10517731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 1915
Study 10517731 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 1915
Study 10517731 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of a thrombus
Number of subjects: 1915
Study 7627447 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 0
Study 7627447 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Number of subjects: 0
Study 7627447 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 0
Study 7627447 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment (control group)
Number of subjects: 0
Study 2043997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracaine (articaine HC1)
Number of subjects: 0
Study 2043997 — intervention group
Group type: COMPARATOR
Intervention: Citanest (prilocaine HC1)
Number of subjects: 0
Study 31164429 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 145
Study 31164429 — intervention group
Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 145
Study 30241679 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) with an Er:YAG laser and a 600-μm tip over the canal entrance
Number of subjects: 50
Study 30241679 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) with an Er:YAG laser and a conical 400-μm fiber tip in the canal entrance
Number of subjects: 50
Study 30241679 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle irrigation (NI)
Number of subjects: 50
Study 30241679 — intervention group
Group type: COMPARATOR
Intervention: Manual-dynamic irrigation
Number of subjects: 50
Study 30241679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation using a size 20 Irrisafe
Number of subjects: 50
Study 26026186 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 103
Study 26026186 — intervention group
Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 103
Study 24156616 — intervention group
Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College
Number of subjects: 2400
Study 22526273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg daily
Number of subjects: 261
Study 22526273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg daily
Number of subjects: 261
Study 22526273 — intervention group
Group type: COMPARATOR
Intervention: Gefarnate 50 mg twice daily
Number of subjects: 261
Study 22526273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (both dosages combined)
Number of subjects: 261
Study 22526273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 261
Study 20107424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 13
Study 20107424 — intervention group
Group type: COMPARATOR
Intervention: Surgery-alone
Number of subjects: 13
Study 17624545 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 18
Study 17624545 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Exercise (EE)
Number of subjects: 18
Study 17624545 — intervention group
Group type: COMPARATOR
Intervention: Control (CEE)
Number of subjects: 18
Study 17624545 — intervention group
Group type: COMPARATOR
Intervention: Control (CRE)
Number of subjects: 18
Study 16142707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 66
Study 16142707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 12126174 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acustimulation of the Pericardium 6 (PC-6) point on the ventral surface of the wrist
Number of subjects: 27
Study 12126174 — intervention group
Group type: COMPARATOR
Intervention: No acustimulation (control group)
Number of subjects: 27
Study 10434980 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing offered on a universal, voluntary basis
Number of subjects: 29
Study 10434980 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine HIV testing recommended to pregnant women
Number of subjects: 29
Study 7572825 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive, psychoeducational intervention program (13 weeks)
Number of subjects: 51
Study 7572825 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 51
Study 1968728 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (A)
Number of subjects: 26
Study 1968728 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (V)
Number of subjects: 26
Study 7438413 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (200 micrograms/day)
Number of subjects: 35
Study 7438413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30412786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid plus bilateral uterine artery ligation (BUAL)
Number of subjects: 62
Study 30412786 — intervention group
Group type: COMPARATOR
Intervention: Bilateral uterine artery ligation (BUAL) alone
Number of subjects: 62
Study 27666722 — intervention group
Group type: EXPERIMENTAL
Intervention: Single GON block with 5 cc 1% lidocaine
Number of subjects: 105
Study 27666722 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage GON block with 5 cc 1% lidocaine
Number of subjects: 105
Study 27666722 — intervention group
Group type: COMPARATOR
Intervention: Triptan withdrawal only
Number of subjects: 105
Study 26489022 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 28
Study 26489022 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Training (MIT)
Number of subjects: 28
Study 24480677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg tofacitinib
Number of subjects: 139
Study 24480677 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tofacitinib
Number of subjects: 139
Study 24480677 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg tofacitinib
Number of subjects: 139
Study 24480677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 21761705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihistamine 10 mg everyday for one week (group CA)
Number of subjects: 40
Study 21761705 — intervention group
Group type: COMPARATOR
Intervention: No loratadine tablets 10 mg everyday for one week (group CB)
Number of subjects: 40
Study 21761705 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (group D)
Number of subjects: 40
Study 19417229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (60 min per day, alternating intervals of hypoxia and normoxia lasting either 3 or 5 min, for 5 consecutive days per week for 3 weeks)
Number of subjects: 27
Study 19417229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypoxia exposure)
Number of subjects: 27
Study 16151422 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan 600 mg/m2 + cyclophosphamide 200 mg/kg
Number of subjects: 94
Study 16151422 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan 16 mg/kg + cyclophosphamide 200 mg/kg + antilymphocyte globulin
Number of subjects: 94
Study 16151422 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 94
Study 16151422 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan 600 mg/m2
Number of subjects: 94
Study 12875349 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (generic gliclazide)
Number of subjects: 0
Study 12875349 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Diamicron)
Number of subjects: 0
Study 10647194 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg at 22.00)
Number of subjects: 20
Study 10647194 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg at 22.00) + Aceten (25 mg at 18.00)
Number of subjects: 20
Study 8690104 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg) and oral contraceptive (150 microg desogestrel and 30 microg ethinyl E2)
Number of subjects: 42
Study 8690104 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (50 mg daily on days 1 to 10 of the menstrual cycle) and estrogen (35 microg ethinyl E2 daily on days 1 to 21)
Number of subjects: 42
Study 1830916 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial appendage removal (Group A, n = 11)
Number of subjects: 23
Study 1830916 — intervention group
Group type: COMPARATOR
Intervention: Right atrial appendage preserved (Group B, n = 12)
Number of subjects: 23
Study 7150460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 36
Study 7150460 — intervention group
Group type: COMPARATOR
Intervention: Oxmetidine 200 mg
Number of subjects: 36
Study 31950597 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with a dose of 66 Gy in 33 fractions from parallel opposed lateral beams.
Number of subjects: 1
Study 30318868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Ambassador Program (MAP); 12-session facilitated group mindfulness-based intervention
Number of subjects: 21
Study 30318868 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 21
Study 28435464 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks
Number of subjects: 30
Study 28435464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25801872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target SBP <140 mm Hg)
Number of subjects: 0
Study 25801872 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment (SBP <180 mm Hg)
Number of subjects: 0
Study 22841616 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 0
Study 21496264 — intervention group
Group type: COMPARATOR
Intervention: Low omega-6 diet
Number of subjects: 40
Study 21496264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low omega-6 plus high omega-3 diet
Number of subjects: 40
Study 18085742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary education program including training in home‐based exercises and guidelines for leisure physical activity (PA)
Number of subjects: 208
Study 18085742 — intervention group
Group type: COMPARATOR
Intervention: Control group received a booklet added to usual medical care
Number of subjects: 208
Study 18085742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary education program
Number of subjects: 208
Study 16792342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (superficial dentin)
Number of subjects: 30
Study 16792342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (deep dentin)
Number of subjects: 30
Study 16792342 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo (superficial dentin)
Number of subjects: 30
Study 16792342 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo (deep dentin)
Number of subjects: 30
Study 16792342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (superficial dentin)
Number of subjects: 30
Study 16792342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (deep dentin)
Number of subjects: 30
Study 14671251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 15
Study 14671251 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 11704025 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-dipping glaucoma patients
Number of subjects: 193
Study 11704025 — intervention group
Group type: COMPARATOR
Intervention: Dippers
Number of subjects: 193
Study 11704025 — intervention group
Group type: COMPARATOR
Intervention: Nondippers
Number of subjects: 193
Study 9142148 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I gastrojejunostomy
Number of subjects: 45
Study 9142148 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II gastrojejunostomy
Number of subjects: 45
Study 9142148 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III gastrojejunostomy
Number of subjects: 45
Study 8184642 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (n = 156)
Number of subjects: 312
Study 8184642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 2467139 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10.0 mg)
Number of subjects: 139
Study 2467139 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25-100 mg)
Number of subjects: 139
Study 28734923 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 238
Study 27550722 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (cefmetazole) alone (IV-only group)
Number of subjects: 515
Study 27550722 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preoperative oral antibiotics (metronidazole and kanamycin) and perioperative intravenous antibiotics (cefmetazole) (oral/IV group)
Number of subjects: 515
Study 23665990 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment (omeprazole 20 mg/12 h, amoxicillin 1 g/12 h, clarithromycin 500 mg/12 h, metronidazole 500 mg/12 h for 10 days)
Number of subjects: 338
Study 23665990 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment (omeprazole 20 mg/12 h and amoxicillin 1 g/12 h for 5 days, followed by omeprazole 20 mg/12 h, clarithromycin 500 mg/12 h, and metronidazole 500 mg/12 h for 5 days)
Number of subjects: 338
Study 23665990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 338
Study 22414838 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper S1-S2-F1-F2
Number of subjects: 30
Study 22414838 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Primary reciprocating files
Number of subjects: 30
Study 20136804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 40
Study 20136804 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40
Study 20136804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (5 IU after delivery)
Number of subjects: 40
Study 20136804 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 40
Study 18806536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative epidural analgesia during major thoracotomy
Number of subjects: 120
Study 18806536 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled thoracic epidural analgesia until thoracostomy tube removal
Number of subjects: 120
Study 18806536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain levels during hospitalization and the first few postoperative months
Number of subjects: 120
Study 18806536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain levels 48 weeks after surgery
Number of subjects: 120
Study 18806536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during the first few postoperative days
Number of subjects: 120
Study 16868694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg b.i.d starting the day of surgery, discontinued 15 days after catheter removal.
Number of subjects: 27
Study 12472790 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073
Number of subjects: 78
Study 12472790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 10716688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of lamivudine 100 mg daily with alpha interferon 10 million units three times weekly for 16 weeks after pretreatment with lamivudine for eight weeks (n=75)
Number of subjects: 230
Study 10716688 — intervention group
Group type: COMPARATOR
Intervention: Alpha interferon 10 million units three times weekly for 16 weeks (n=69)
Number of subjects: 230
Study 10716688 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily for 52 weeks (n=82)
Number of subjects: 230
Study 9374604 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-witness information (incorrect)
Number of subjects: 0
Study 9374604 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestive questioning paired with incorrect co-witness information
Number of subjects: 0
Study 9374604 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed memory test (48 hours after initial questioning)
Number of subjects: 0
Study 1555905 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-diet (65% carbohydrate)
Number of subjects: 7
Study 1555905 — intervention group
Group type: COMPARATOR
Intervention: C-diet (39% carbohydrate)
Number of subjects: 7
Study 3728926 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg + intravenous naloxone 2 mg for 12 hours
Number of subjects: 45
Study 3728926 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 4 mg
Number of subjects: 45
Study 3728926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone
Number of subjects: 45
Study 3728926 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 mg morphine intramuscularly + 20 ml epidural saline)
Number of subjects: 45
Study 29512481 — intervention group
Group type: EXPERIMENTAL
Intervention: DPIV 1 μg with alum, AS01E, or AS03B
Number of subjects: 100
Study 29512481 — intervention group
Group type: EXPERIMENTAL
Intervention: DPIV 4 μg with alum
Number of subjects: 100
Study 29512481 — intervention group
Group type: EXPERIMENTAL
Intervention: DPIV 1 μg + AS03B
Number of subjects: 100
Study 29512481 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 27919234 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT (B-CBT) consisting of six face-to-face CBT sessions alternated with six to eight online modules (NoDep)
Number of subjects: 130
Study 27919234 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) defined as 12 sessions of face-to-face CBT
Number of subjects: 130
Study 23446088 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 treatment (up to 3, 60-minute treatments)
Number of subjects: 272
Study 23446088 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 treatment
Number of subjects: 272
Study 22723310 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 242
Study 22723310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 19164305 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing with water-soluble contrast medium (WSCM)
Number of subjects: 334
Study 19164305 — intervention group
Group type: COMPARATOR
Intervention: No flushing (control group)
Number of subjects: 334
Study 17563157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 60